about
Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formationChanges in bowel microbiota induced by feeding weanlings resistant starch stimulate transcriptomic and physiological responses.The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel diseaseThe anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage.Role of mammalian lignans in the prevention and treatment of prostate cancer.Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cellsHuman oral isolate Lactobacillus fermentum AGR1487 reduces intestinal barrier integrity by increasing the turnover of microtubules in Caco-2 cells.Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.Virgin olive oil phenolics extract inhibit invasion of HT115 human colon cancer cells in vitro and in vivo.Anti-proliferative effects of physiological concentrations of enterolactone in models of prostate tumourigenesis.Chickpea (Cicer arietinum) and other plant-derived protease inhibitor concentrates inhibit breast and prostate cancer cell proliferation in vitro.Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro.Colon-available raspberry polyphenols exhibit anti-cancer effects on in vitro models of colon cancer.Potential anti-cancer effects of virgin olive oil phenols on colorectal carcinogenesis models in vitro.Assessment of the anti-genotoxic, anti-proliferative, and anti-metastatic potential of crude watercress extract in human colon cancer cellsAltered metabolic gene expression in the brain of a triprolyl-human amylin transgenic mouse model of type 2 diabetes
P50
Q33767034-901C0F65-73D2-4CB4-BB1F-900E05E04B3EQ34338232-636804D4-06B5-43F7-89BF-DFB3A723C9D5Q34411654-61DC4CF6-1333-4F76-8A44-3EC648CEB999Q34577999-93D60328-4B6D-4DBA-80C3-684F17DE5611Q36223533-DC34C7F8-5BB4-4801-8E95-8C3320FD6490Q37295725-A781631D-AFFF-4182-B4B4-81D3EEFD0A5BQ37309403-EE5ADEF4-F4FB-4BA5-B7D7-58BA955574CFQ38701598-5EF0A690-E8DD-4382-B452-EE4751C2B833Q38994243-DD91A91C-DE64-451F-85BA-FBA462950A46Q39245540-A1FE509F-DD5D-45E3-8107-2174F5CF757DQ39337584-D15A6758-94CC-4222-B173-ED4E97B90881Q39993772-5C94E3AF-4A62-4A14-9E53-F11CCBEE654EQ41865929-E42A11B5-75BA-466F-8149-9CA1B97806C5Q53358277-1D201104-0118-447E-A454-818C09E24B74Q79254696-C7346FB8-C0F1-4A27-BD47-8C245802365CQ90640837-9A256003-F333-4977-BD2C-F302CD1729C7
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-8247-2199
@en
name
Mark McCann
@ast
Mark McCann
@en
Mark McCann
@es
Mark McCann
@nl
type
label
Mark McCann
@ast
Mark McCann
@en
Mark McCann
@es
Mark McCann
@nl
prefLabel
Mark McCann
@ast
Mark McCann
@en
Mark McCann
@es
Mark McCann
@nl
P106
P1153
8694468500
P21
P31
P496
0000-0001-8247-2199